

Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims

1-12. (Canceled).

13. (Currently Amended) A method of treating ~~an affective disorder~~ alcohol addiction, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, premenstrual syndrome, or neuropathic pain which comprises administering to a patient a therapeutically effective amount of ~~a bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the affective disorder is alcohol addiction, an anxiety disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, seasonal affective disorder, or premenstrual syndrome.

14-60. (Canceled).

61. (Currently amended) The method of claim 13 wherein the effective amount of ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 1 mg to about 750 mg per day.

62. (Currently amended) The method of claim 13 wherein the effective amount of ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 5 mg to about 700 mg per day.

63. (Currently amended) The method of claim 13 wherein the effective amount of ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 10 mg to about 650 mg per day.

64. (Currently amended) The method of claim 13 wherein ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered orally, transdermally, and mucosally.

65. (Currently amended) The method of claim 64 wherein ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered orally.

66. (Currently amended) The method of claim 64 wherein ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered transdermally.

67. (Currently amended) The method of claim 64 wherein ~~the bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered mucosally.

68. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is alcohol addiction is treated.

69. (Canceled).

70. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is a bipolar or manic condition is treated.

71. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is bulimia is treated.

72. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is chronic fatigue syndrome is treated.

73. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is narcolepsy is treated.

74. (Canceled).

75. (Currently amended) The method of claim 13 wherein ~~the affective disorder~~ is premenstrual syndrome is treated.

76. (Currently amended) The method of claim 13 wherein the ~~bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol is in the form of an acceptable salt.

77. (Currently amended) The method of claim 13 wherein the ~~bupropion metabolite~~ optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol is in the form of a solvate.

78. (Canceled).

79. (New) The method of claim 13, wherein neuropathic pain is treated.